Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Ratios

Lyra Therapeutics (LYRA) Change in Acquisitions & Divestments (2023 - 2024)

Lyra Therapeutics has reported Change in Acquisitions & Divestments over the past 2 years, most recently at $28.1 million for Q4 2024.

Quarterly results put Change in Acquisitions & Divestments at $28.1 million for Q4 2024, down 41.62% from a year ago — trailing twelve months through Dec 2024 was $130.6 million (up 17.77% YoY), and the annual figure for FY2024 was $130.6 million, up 17.77%.
Change in Acquisitions & Divestments for Q4 2024 was $28.1 million at Lyra Therapeutics, up from $21.0 million in the prior quarter.
Over the last five years, Change in Acquisitions & Divestments for LYRA hit a ceiling of $51.0 million in Q2 2024 and a floor of $9.8 million in Q1 2023.